Moderna (MRNA) Reports Earnings Tomorrow: What To Expect [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
Moderna met analysts' revenue expectations last quarter, reporting revenues of $966 million, down 65.6% year on year. It was a slower quarter for the company, with full-year revenue guidance missing analysts' expectations significantly. Is Moderna a buy or sell going into earnings? Read our full analysis here, it's free This quarter, analysts are expecting Moderna's revenue to decline 29.4% year on year to $117.9 million, improving from the 91% decrease it recorded in the same quarter last year. Adjusted loss is expected to come in at -$3.11 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Moderna has missed Wall Street's revenue estimates twice over the last two years. Looking at Moderna's peers in the biotechnology segment, some have already reported their Q1 results, giving us a hint as to what we can expect. AbbVie delivered year-on-y
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences (NASDAQ:GILD) was given a new $135.00 price target on by analysts at Sanford C. Bernstein.MarketBeat
- Update: Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise [Yahoo! Finance]Yahoo! Finance
- Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences to Present at Upcoming Investor ConferenceBusiness Wire
- Biopharma climbs higher as 9 drugmakers ink ‘pandering' drug price deals with Trump [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- 12/15/25 - Form 144
- GILD's page on the SEC website